ArticleJournal of nanobiotechnology2026
Injectable multi-component hydrogels for the treatment of ascites caused by hepatocellular carcinoma via anti-tumor and reduction of ascites generation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide, and malignant ascites (MA) caused by HCC is almost incurable. However, the efficacy of chemotherapy is limited by poor tumor drug targeting and the presence of an immunosuppressive microenvironment. Therefore, it is urgent to find drugs for dual-therapy that have both anti-tumor effect and reduction of MA production. Inspired by self-assembly of two molecules, we enriched the effective parts of Genkwa Flos (GK), which was decocted with glycyrrhizic acid (GA) from licorice, one pot of green synthesis of an injectable multi-component hydrogel of TCM (GK-GA). The GK-GA hydrogel demonstrated excellent injectability and sustained retention properties in the peritoneal cavity following intraperitoneal administration. In vivo pharmacodynamic experiments demonstrated potent therapeutic efficacy, achieving a 47.62% reduction in ascites formation at 6.25 mg/kg. By integrating network pharmacology, transcriptomics, and metabolomics, mechanistic studies revealed its dual therapeutic pathways against MA: (1) as a pro-apoptotic agent that significantly induces tumor cell apoptosis by elevating intracellular reactive oxygen species (ROS) levels via mitochondrial membrane potential depolarization, and modulat related proteins in the PI3K-AKT signaling pathway, and (2) as a metabolic regulator that effectively suppresses ascites formation by normalizing the aldosterone metabolic pathway. The method of self-assembly of supramolecular hydrogel by enriching the effective parts is more in line with the characteristics of multi-component, multi-pathway and multi-target comprehensive prevention and treatment of diseases in TCM, and offers a promising approach for novel drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.